Lucerastat Fails to Lessen Neuropathic Pain in Phase 3 Trial

Lucerastat Fails to Lessen Neuropathic Pain in Phase 3 Trial

311246

Lucerastat Fails to Lessen Neuropathic Pain in Phase 3 Trial

Lucerastat, an investigational substrate reduction therapy for Fabry disease, has failed to outperform placebo at reducing neuropathic pain in patients, updated results from the MODIFY Phase 3 trial show. The findings mean that Idorsia‘s MODIFY study (NCT03425539) did not meet its primary goal, despite lucerastat being well tolerated and reducing the levels of globotriaosylceramide (Gb3) — the fat molecule that builds up and causes damage in Fabry patients. As most patients chose to enter MODIFY’s extension…

You must be logged in to read/download the full post.